23.05.2024 - Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with additional data expected in the second half of 2024 ... Seite 1

Related Keywords

Illinois , United States , Chicago , Watertown , American , Jared Gollob , Kymera Therapeutics Inc , Nasdaq , American Society Of Clinical Oncology , American Society , Clinical Oncology , Annual Meeting , Medical Officer , Response Assessments ,